Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Harvard Business School
Johnson and Johnson
Mallinckrodt

Last Updated: September 26, 2022

Tecovirimat - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for tecovirimat and what is the scope of freedom to operate?

Tecovirimat is the generic ingredient in one branded drug marketed by Siga Technologies and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tecovirimat has ninety-one patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for tecovirimat
International Patents:91
US Patents:9
Tradenames:1
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 24
Clinical Trials: 6
Patent Applications: 126
DailyMed Link:tecovirimat at DailyMed
Recent Clinical Trials for tecovirimat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
United States Department of DefensePhase 3
Medical CBRN Defense Consortium (MCDC)Phase 3
SIGA TechnologiesPhase 3

See all tecovirimat clinical trials

US Patents and Regulatory Information for tecovirimat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Siga Technologies TPOXX tecovirimat SOLUTION;INTRAVENOUS 214518-001 May 18, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Siga Technologies TPOXX tecovirimat SOLUTION;INTRAVENOUS 214518-001 May 18, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Siga Technologies TPOXX tecovirimat SOLUTION;INTRAVENOUS 214518-001 May 18, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Siga Technologies TPOXX tecovirimat SOLUTION;INTRAVENOUS 214518-001 May 18, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for tecovirimat

Country Patent Number Title Estimated Expiration
Brazil 112013002646 See Plans and Pricing
Canada 2866037 PRODUITS CHIMIQUES, COMPOSITIONS ET PROCEDES DE TRAITEMENT ET DE PREVENTION DES INFECTIONS A ORTHOPOXVIRUS ET DES MALADIES ASSOCIEES (CHEMICALS, COMPOSTIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORT HOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008130348 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2004112718 See Plans and Pricing
China 101702904 Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases See Plans and Pricing
China 105111131 Polymorphic forms of ST-246 and methods of preparation See Plans and Pricing
Brazil 112012023743 formas polimórficas st-246 e métodos de preparação See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for tecovirimat

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1638938 301177 Netherlands See Plans and Pricing PRODUCT NAME: TECOVIRIMAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1600/001 20220107
1638938 2022C/521 Belgium See Plans and Pricing PRODUCT NAME: TECOVIRIMAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1600 20220107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
McKesson
Medtronic
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.